MedTrace Logo

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

NCT03228537 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-05-01

Study results available
· View outcomes & findings →

Summary

This phase I pilot trial studies how well atezolizumab, pemetrexed disodium, cisplatin, and surgery with or without radiation therapy works in treating patients with stage I-III pleural malignant mesothelioma. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving atezolizumab, pemetrexed disodium, and cisplatin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving atezolizumab after surgery may kill any remaining tumor cells.

Conditions

  • Biphasic Mesothelioma
  • Epithelioid Mesothelioma
  • Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7
  • Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7
  • Stage IB Pleural Diffuse Malignant Mesothelioma AJCC v7
  • Stage II Pleural Diffuse Malignant Mesothelioma AJCC v7
  • Stage III Pleural Diffuse Malignant Mesothelioma AJCC v7

Interventions

DRUG

Atezolizumab

Given IV

DRUG

Cisplatin

Given IV

PROCEDURE

Extrapleural Pneumonectomy

Undergo EPP

DRUG

Pemetrexed Disodium

Given IV

PROCEDURE

Pleurectomy

Undergo PD

RADIATION

Radiation Therapy

Undergo RT

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Anne S Tsao · SWOG Cancer Research Network

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-16
Primary Completion
2022-10-01
Completion
2026-09-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03228537 on ClinicalTrials.gov